Adaptimmune Therapeutics PLC (ADAP)
0.8246
+0.02
(+3.10%)
USD |
NASDAQ |
Nov 04, 16:00
0.8246
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Enterprise Value: 14.71M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 14.71M |
| October 31, 2024 | -4.266M |
| October 30, 2024 | -11.63M |
| October 29, 2024 | -9.662M |
| October 28, 2024 | -1.300M |
| October 25, 2024 | -1.223M |
| October 24, 2024 | 1.974M |
| October 23, 2024 | 10.90M |
| October 22, 2024 | 17.32M |
| October 21, 2024 | 20.85M |
| October 18, 2024 | 25.68M |
| October 17, 2024 | 25.37M |
| October 16, 2024 | 32.92M |
| October 15, 2024 | 35.22M |
| October 14, 2024 | 34.99M |
| October 11, 2024 | 33.07M |
| October 10, 2024 | 34.97M |
| October 09, 2024 | 37.70M |
| October 08, 2024 | 42.59M |
| October 07, 2024 | 42.89M |
| October 04, 2024 | 53.38M |
| October 03, 2024 | 39.06M |
| October 02, 2024 | 33.87M |
| October 01, 2024 | 45.81M |
| September 30, 2024 | 53.23M |
| Date | Value |
|---|---|
| September 27, 2024 | 60.08M |
| September 26, 2024 | 49.80M |
| September 25, 2024 | 45.27M |
| September 24, 2024 | 58.49M |
| September 23, 2024 | 50.08M |
| September 20, 2024 | 64.91M |
| September 19, 2024 | 68.47M |
| September 18, 2024 | 76.14M |
| September 17, 2024 | 78.70M |
| September 16, 2024 | 78.70M |
| September 13, 2024 | 94.04M |
| September 12, 2024 | 91.48M |
| September 11, 2024 | 86.37M |
| September 10, 2024 | 86.37M |
| September 09, 2024 | 94.04M |
| September 06, 2024 | 88.93M |
| September 05, 2024 | 94.04M |
| September 04, 2024 | 106.83M |
| September 03, 2024 | 119.62M |
| August 30, 2024 | 134.96M |
| August 29, 2024 | 134.96M |
| August 28, 2024 | 122.17M |
| August 27, 2024 | 127.29M |
| August 26, 2024 | 150.31M |
| August 23, 2024 | 119.62M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-98.43M
Minimum
Mar 15 2022
1.554B
Maximum
Jun 04 2020
240.60M
Average
121.53M
Median
Enterprise Value Benchmarks
| Biodexa Pharmaceuticals PLC | -2.478M |
| Verona Pharma PLC | 2.557B |
| NuCana PLC | -11.26M |
| Autolus Therapeutics PLC | 225.39M |
| Bicycle Therapeutics PLC | 677.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 69.52M |
| Revenue (Quarterly) | 128.23M |
| Total Expenses (Quarterly) | 59.53M |
| EPS Diluted (Quarterly) | 0.24 |
| Profit Margin (Quarterly) | 54.22% |
| Earnings Yield | -36.38% |
| Normalized Earnings Yield | -36.34 |